Gynesonics appoints Dave Pacitti to its Board of Directors as Chair alongside Dr. Karen Talmadge remaining as Independent Director

– USA, CA –  Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the appointment of Dave Pacitti as Chair of the Board of Directors, succeeding Dr. Karen Talmadge who remains on the Board as Independent Director.

David is the medical device executive and current President and Head of Siemens Healthineers for The Americas.

“We are pleased to have Dave Pacitti join the Board of Directors as the new Board Chair. With his direct experience in operations and rapid commercialization, along with his proven leadership, Dave has a unique ability to support our commercial growth.” said CEO, Christopher Owens.

He added: “I would also like to express my deepest gratitude to scientist and entrepreneur, Karen Talmadge, Ph.D. She provided Gynesonics with critically important guidance through our clinical development phase and initial product launch in her prior role as Board Chair. Karen has and will continue to make tremendous contributions to this organization. I am delighted to have her expertise retained as she transitions to an independent Board Director.”

About David Pacitti

Mr. Pacitti is leading the marketing, sales, service, and support functions in North America and Latin America for Siemens Healthineers. This multi-billion-dollar business has more than 10,000 employees and includes medical imaging, laboratory diagnostics, therapy solutions, and services.

“I am incredibly excited to join the Gynesonics team and lead the Board of Directors as we work together to improve women’s lives around the world,” said Dave Pacitti. “The Sonata® System represents a leap forward by bringing imaging technology together with proven clinical science to provide women with a minimally invasive and incision-less treatment alternative for symptomatic uterine fibroids. I’m excited to work with the team at Gynesonics to bring this important advancement to more women and focus on the commercial success of the organization.”

Before his roles with Siemens, Mr. Pacitti was Division VP of the U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular for two years overseeing the company’s business in North America, playing pivotal roles in key launches, including Abbott Vascular’s first drug-eluting stent franchise and structural heart franchise. In addition, Mr. Pacitti was VP, Commercial Operations at Abbott Vascular from 2009 to 2013, and VP of Global Marketing from 2006 to 2009. Early in Pacitti’s career, he was a sales representative in the Siemens Healthineers Molecular Imaging business.

Mr. Pacitti serves on the boards of Apollo Endo-Surgery, the Advanced Medical Technology Association, the University City Science Center in Philadelphia, PA, the National Electrical Manufacturers Association, and the Siemens Foundation. He is also a member of the CEO Council for Growth at the Chamber of Commerce for Greater Philadelphia, the Children’s Hospital of Philadelphia Corporate Council, the Medical University of South Carolina President’s Advisory Group, and the NextGen Advisory Board for the University of Missouri.

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real-time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface, enabling the operator to target fibroids and optimize treatment. The Sonata system provides incision-free transcervical access for uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. The Sonata System is CE marked and is approved for sale in the European Union and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.